Cholesterol Lowering in Older Adults: Should We Wait for Further Evidence?

• Published in: Current atherosclerosis reports Vol. 26; no. 9; pp. 521 - 536
• Main Authors: Jamil, Yasser A., Cohen, Rachel, Alameddine, Dana K., Deo, Salil V., Kumar, Manish, Orkaby, Ariela R.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.09.2024
• Subjects: Aged; Angiology; Anticholesteremic Agents - therapeutic use; Atherosclerosis - prevention & control; Cardiology; Cardiovascular Diseases - prevention & control; Cholesterol, LDL - blood; Cholesterol, LDL - drug effects; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Medicine; Medicine & Public Health; Primary Prevention - methods; Review; Risk Assessment - methods; Secondary Prevention - methods; Topical Collection on Coronary Heart Disease; Aging; Lipid lowering therapy; Cardiovascular Diseases; Primary Prevention; Secondary Prevention; Dyslipidemia
• ISSN: 1523-3804; 1534-6242; 1534-6242
• DOI: 10.1007/s11883-024-01224-4

Purpose of Review Current guidelines for primary and secondary prevention of cardiovascular events in adults up to age 75 years are well-established. However, recommendations for lipid-lowering therapies (LLT), particularly for primary prevention, are inconclusive after age 75. In this review, we focus on adults ≥ 75 years to assess low-density lipoprotein-cholesterol (LDL-C) as a marker for predicting atherosclerotic cardiovascular disease (ASCVD) risk, review risk assessment tools, highlight guidelines for LLT, and discuss benefits, risks, and deprescribing strategies. Recent Findings The relationship between LDL-C and all-cause mortality and cardiovascular outcomes in older adults is complex and confounded. Current ASCVD risk estimators heavily depend on age and lack geriatric-specific variables. Emerging tools may reclassify individuals based on biologic rather than chronologic age, with coronary artery calcium scores gaining popularity. After initiating LLT for primary or secondary prevention, target LDL-C levels for older adults are lacking, and non-statin therapy thresholds remain unknown, relying on evidence from younger populations. Shared decision-making is crucial, considering therapy's time to benefit, life expectancy, adverse events, and geriatric syndromes. Deprescribing is recommended in end-of-life care but remains unclear in fit or frail older adults. Summary After an ASCVD event, LLT is appropriate for most older adults, and deprescribing can be considered for those approaching the last months of life. Ongoing trials will guide statin prescription and deprescribing among older adults free of ASCVD. In the interim, for adults ≥ 75 years without a limited life expectancy who are free of ASCVD, an LLT approach that includes both lifestyle and medications, specifically statins, may be considered after shared decision-making.